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Preeclampsia is a complex multifactorial disease. Placental oxidative stress, a result
of deﬁcient spiral artery remodeling, plays an important role in the pathophysiology of
preeclampsia. Antiangiogenic factors secreted frommalperfused placenta are instrumental
in mediating maternal endothelial dysfunction and consequent symptoms of preeclampsia;
the mechanism is likely to involve increased ET-1 secretion and reduced NO bioavailability.
Therapeutic interventions so far remain only experimental and there is no established
remedy for the treatment of preeclampsia. This review concentrates on the evidence
for the therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and
statins. These compounds display pleitropic antioxidant, anti-inﬂammatory, and pro-
angiogenic effects in animal and in vitro studies. Although clinical trials on the use of
antioxidant vitamins in pregnancy proved largely unsuccessful, the scope for their use
still exists given the beneﬁcial cardioprotective effects of antioxidant-rich Mediterranean
diet, periconceptual vitamin use and the synergistic effect of vitamin C and L-arginine.
Encouraging clinical evidence exists for the use of NOdonors, and a clinical trial is underway
testing the effect of statins in treatment of preeclampsia. H2S recently emerged as a novel
therapeutic agent for cardiovascular disease, and its beneﬁcial effects were also tested in
animal models of preeclampsia. It is risky to prescribe any medication to pregnant women
on a large scale, and any future therapeutic intervention has to be well tested and safe.
Many of the compounds discussed could be potential candidates.
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THE SYNDROME OF PREECLAMPSIA
Preeclampsia affects 3–5% of all pregnancies. The traditional def-
inition of preeclampsia as de novo onset of hypertension and
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proteinuria after 20 weeks of gestation has been recently modi-
ﬁed by the American College of Obstetricians and Gynecologists
in recognition of the syndromic nature of preeclampsia. In the
absence of proteinuria, preeclampsia is diagnosed as hypertension
in association with thrombocytopenia, impaired liver function,
new development of renal insufﬁciency, pulmonary edema, or
new-onset cerebral or visual disturbances (American College
of Obstetricians Gynecologists [ACOG], 2013). Hypertension,
proteinuria, edema, and other systemic manifestations of the
syndrome of preeclampsia are the direct consequences of mater-
nal endothelial dysfunction. The syndrome is a major cause of
maternal and fetal morbidity and mortality, and results in mild to
severe microangiopathy of target organs, including the brain, liver,
kidney, and placenta (Sibai et al., 2005). Severe maternal compli-
cations include seizures (eclampsia), stroke, renal failure, liver
failure, and/or rupture, HELLP syndrome (hemolysis, elevated
liver enzymes, and low platelets), and death (Young et al., 2010).
Fetal complications include prematurity due to preterm deliv-
ery, fetal growth restriction, fetal/neonatal hypoxic neurological
injury, perinatal death, and long-term cardiovascular morbidity
associated with low birth weight (Sibai et al., 2005).
Preeclampsia (PE) is a complex multifactorial disease; many
factors, including genetic predisposition, immunological interac-
tions, maternal endothelial function and environmental factors
interact and culminate in the disease manifestation. In recent
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years, PE is commonly subdivided into early and late-onset, as
the two conditions seem to have different underlying etiologies.
Both early and late onset diseases present with abnormal placen-
tal perfusion and oxidative stress, however, poor placentation and
deﬁcient conversion of maternal spiral arteries only underlie the
pathology of the early onset disease, whilst the late onset condi-
tion is associated with normal uterine spiral artery conversion
and normally grown baby (Huppertz, 2008). Redman recently
proposed a novel hypothesis for the pathology of late-onset PE,
suggesting an intrinsic cause due to microvillous overcrowd-
ing, as placental growth reaches its functional limit. In both
conditions, oxidatively stressed syncytiotrophoblast over-secrets
proteins that perturb maternal angiogenic balance (Redman et al.,
2014). Abnormal placentation is recognized as a main prerequi-
site for the pathogenesis of early onset preeclampsia. The disease
seems to progress in two stages; in stage I (preclinical), poor
development of the early placenta leads to deﬁcient remodeling
of maternal spiral arteries and consequent ischemia-reperfusion
type injury of the placenta and oxidative stress. In stage II (clin-
ical), the ischemic/malperfused placenta triggers the secretion of
a mixture of placental factors, including antiangiogenic factors,
proinﬂammatory cytokines and apoptotic debris that culminate in
an enhanced maternal inﬂammatory response and in turn induce
systemic endothelial dysfunction and the maternal syndrome of
preeclampsia (Roberts and Cooper, 2001; Redman and Sargent,
2005).
In conditions of PE and IUGR which result in fetal hypoxia,
there is a tendency to refer to fetoplacental hypoxia as the under-
lying cause. This concept has been challenged by several groups
who advocate caution when interpreting results from pregnancies
complicated by PE and IUGR (Kingdom and Kaufmann, 1997;
Mayhew et al., 2004; Huppertz et al., 2014). These studies sug-
gest that late-onset PE and late onset IUGR with present end
diastolic ﬂow (EDF) are associated with ischemic uteroplacental
hypoxia in which the delivery of blood to the intervillous space is
compromised due to deﬁcient trophoblast invasion. This placen-
tal malperfusion results in ischemia-reperfusion injury affecting
trophoblast and vascular endothelium, however fetal extraction
of O2 is not compromised and there is evidence of increased
placental branching angiogenesis (Mayhew et al., 2004). In con-
trast, pregnancies complicated by early onset PE, which is usually
accompanied with early onset IUGR with absent/reversed EDF
are often referred to as ‘placental hyperoxia’ due to compro-
mised fetoplacental blood ﬂow which fails to extract oxygen
from the intervillous space, leading to poor fetal oxygenation
and higher than normal intervillous oxygen levels (postpla-
cental hypoxia; Kingdom and Kaufmann, 1997; Mayhew et al.,
2004).
Medical intervention in preeclampsia remains limited, cen-
tering on management of maternal hypertension and systemic
complications, seizure prevention with magnesium sulfate, and
delivering the fetus before term as a measure of treating mater-
nal effects and preventing further growth restriction. However,
any beneﬁts this confers are offset by the complications of pre-
maturity. Hence, identifying interventions that would modulate
the pathological processes involved in the disease pathogene-
sis are key to intervening effectively in preeclampsia to improve
maternal and fetal prognosis. This review will focus on the role
of angiogenic and antiangiogenic factors in mediating maternal
endothelial dysfunction and explore some therapeutic strategies
aimed at targeting these factors in order to reverse/ameliorate the
disease pathology.
EVIDENCE FOR THE ROLE OF ANGIOGENIC FACTORS IN
PREECLAMPSIA
Placental vasculature is plastic and changes constantly through-
out pregnancy to facilitate the rapid growth, and supply the
increasing metabolic needs of the growing fetus (Charnock-
Jones et al., 2004). Normal placental development is regulated by
proangiogenic and antiangiogenic factors. The processes of vas-
culogenesis, de novo formation of blood vessels from precursor
cells, and angiogenesis, creation of vessels from pre-existing ves-
sels, are critical in the fetal and placental development for effective
transport of oxygen, nutrients and fetal growth and develop-
ment (Charnock-Jones et al., 2004). In contrast, angiogenesis is
a rare event in adult vascular networks under physiological con-
ditions, being limited to organs of the female reproductive tract
(endometrium, ovary, placenta). Appearance of new blood vessel
growth in other organs is regarded as pathological, and can be
involved in conditions such as wound healing, tumor growth, and
retinopathy.
Placental abnormalities lead to secretion of a mixture of pro-
teins that stimulate maternal endothelium and result in the disease
presentation. Recently, circulating antiangiogenic proteins, sol-
uble vascular endothelial growth factor receptor 1 [VEGF-R1,
also referred to as soluble fms-like tyrosine kinase (sFlt1)] and
soluble TGF-β co-receptor endoglin (sEng), have been impli-
cated in the pathogenesis of many of the maternal features of
preeclampsia. We will ﬁrst consider the role of proangiogenic fac-
tors, VEGF and transforming growth factor (TGF-β), and their
receptors in vascular homeostasis (Table 1). VEGFs are a family
of secreted dimeric glycoproteins involved in vasculogenesis and
angiogenesis. In humans and other mammals, VEGF-A (referred
here as VEGF) and its placental homologue placental growth
factor (PlGF) are the most important members with proangio-
genic activity (Keck et al., 1989; Leung et al., 1989; Maglione et al.,
1991). VEGF promotes survival and proliferation of endothelial
cells and induces vascular permeability (Keck et al., 1989; Leung
et al., 1989). Two VEGF receptors, VEGF-R1 (Flt-1) and VEGF-
R2 (Flk-1/KDR) are present on endothelial cells. VEGF binds
to both receptors whilst PlGF homodimers bind exclusively to
VEGF-R1. VEGF-R2 it thought to primarily mediate the actions
of VEGF on endothelial cells. The function of VEGF-R1 is less
well deﬁned, although it is thought to modulate VEGF-R2 sig-
naling. Another function of VEGF-R1 is to act as a decoy receptor
(sFlt-1), sequesteringVEGF fromVEGF-R2 binding (Table 1; Park
et al., 1994; Waltenberger et al., 1994; Keyt et al., 1996). TGF-β
is another important molecule involved in angiogenesis, it has
been implicated in the development of the vasculature (Oshima
et al., 1996). TGF-β signals via binding to both type I (ALK1
and ALK5) and type II receptors. In addition, TGF-β signaling
in the vasculature involves coreceptors that act to modulate its
effects. Endoglin (CD105) is a TGF-β coreceptor expressed by
endothelial cells and placental syncytiotrophoblast. TGF-β effects
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Table 1 | A brief description of function of angiogenic and antiangiogenic growth factors and their receptors in pregnancy.
Molecules Function and changes in pathological conditions
Angiogenic Factors
VEGF-A Potent angiogenic protein and trophic cytokine essential for endothelial integrity
Free VEGF concentration decreased in preeclamptic women at disease presentation and even before the onset of disease
(Maynard et al., 2003; Taylor et al., 2003; Levine et al., 2004)
PlGF Key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PlGF during pregnancy
is the placental trophoblast
Reduced in maternal plasma in preeclampsia (Maynard et al., 2003; Taylor et al., 2003; Levine et al., 2004)
TGF-β Important molecule involved in angiogenesis, it has been implicated in the development of the vasculature (Oshima et al., 1996).
In vitro effects are concentration-dependent, inducing proliferation and migration of endothelial cells at low doses (ALK1
mediated), and inhibiting proliferation and migration of endothelial cells at high doses (via ALK5; Goumans et al., 2002). Important
modulator of VEGF signaling, further linkingTGF-β to angiogenesis (Shao et al., 2009)
Receptors
VEGF-R1 (Flt-1) All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGF-Rs) on the cell
surface, causing them to dimerize and become activated through transphosphorylation
VEGF-R2 (Flk-1) VEGF-A binds to VEGF-R1 (Flt-1) and VEGF-R2 (KDR/Flk-1), whilst PlGF only binds to VEGF-R1. VEGF-R2 appears to mediate almost
all of the known cellular responses to VEGF. The function of VEGF-R1 is less well deﬁned, although it is thought to modulate
VEGF-R2 signaling. Another function of VEGFR-1 is to act as a decoy receptor (sFlt-1), sequestering VEGF from VEGF-R2 binding




TGF-β signals via binding to both type I (ALK1 and ALK5) and type II receptors. In addition, TGF-β signaling in the vasculature
involves coreceptors, e.g., endoglin (CD105), that act to modulate its effects. Endoglin is a membrane glycoprotein expressed by
endothelial cells and placental syncytiotrophoblast. It has a crucial role in angiogenesis, therefore, making it an important protein
for tumor growth, survival and metastasis of cancer cells to other locations in the body (Goumans et al., 2002; Shao et al., 2009).
Antiangiogenic Factors
sFlt-1 Formed by alternative splicing of the pre-mRNA encoding VEGF-R1. It can bind circulating VEGF and PlGF as it lacks the
cytoplasmic and transmembrane domain, thus preventing their interactions with endogenous receptors. Increased in maternal
plasma in preeclampsia (Taylor et al., 2003; Levine et al., 2004, 2006; Chaiworapongsa et al., 2005; Steinberg et al., 2009)
sEng Reduces endothelial tube formation in vitro and leads to increased capillary permeability. It blocks TGF-β1-induced vasodilation
through interference of TGF-β1 binding to its receptor (Venkatesha et al., 2006). sEng is elevated in the sera of preeclamptic
women, its circulating levels increase markedly beginning 2–3 months before the onset of preeclampsia, concentrations
correlating with disease severity (Levine et al., 2006)
in vitro seemconcentration-dependent, inducingproliferation and
migration of endothelial cells at low doses (ALK1 mediated), and
inhibiting proliferation and migration of endothelial cells at high
doses (via ALK5; Goumans et al., 2002). In addition, TGF-β is an
important modulator of VEGF signaling, further linking TGF-β
to angiogenesis (Table 1; Shao et al., 2009).
The vascular endothelium relies on proangiogenic factors.
Release of placentally derived antiangiogenic factors into mater-
nal circulation is thus likely to cause angiogenic factor imbalance,
leading to endothelial dysfunction that manifests as the symp-
toms of preeclampsia. Two such factors, sFlt-1 and sEng, have
been implicated in the pathophysiology of preeclampsia (Table 1).
Soluble Flt-1 is formed by alternative splicing of the pre-mRNA
encoding VEGF-R1. It can bind circulating VEGF and PlGF as
it lacks the cytoplasmic and transmembrane domain, thus pre-
venting their interactions with endogenous receptors. Soluble
endoglin receptor sEng reduces endothelial tube formation in vitro
and leads to increased capillary permeability. It blocks TGF-β1-
induced vasodilation through interference of TGF-β1 binding to
its receptor, this effect is likely to involve NO (Venkatesha et al.,
2006).
Let us now consider the clinical and experimental evidence for
the role of angiogenic factor imbalance in the pathophysiology
of preeclampsia. The circulating levels of two placental-derived
antiangiogenic factors, sFlt-1 and sEng, are elevated in the circu-
lation of women with preeclampsia, and may begin to rise even
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before the onset of clinical symptoms, whereas the circulating
concentrations of VEGF and PlGF are reduced in preeclamp-
tic women at disease presentation and even before the onset of
clinical symptoms (Taylor et al., 2003; Levine et al., 2004, 2006;
Chaiworapongsa et al., 2005; Steinberg et al., 2009). The levels of
circulating sFlt-1 increase and PlGF decrease during the last two
months of pregnancy in normotensive women, however, these
changes are signiﬁcantly more pronounced in women who later
develop preeclampsia and occur on average about 5 weeks before
the onset of the disease (Levine et al., 2004). sEng is elevated in
the sera of preeclamptic women, its circulating levels increase
markedly beginning 2–3 months before the onset of preeclamp-
sia, concentrations correlating with disease severity (Levine et al.,
2006). However, it should be noted that despite the strong evidence
linking angiogenic factor imbalance with PE, not all preeclamptic
patients present with increased sFlt-1 and decreased VEGF/PlGF
levels, and other mechanisms such as inﬂammation, oxidative
stress, immunological interactions,maternal endothelial function,
etc. also play an important role in the pathophysiology of this
multifactorial disease.
Animal studies provide strong evidence linking sFlt-1 to the
pathogenesis of preeclampsia. Although animal models do not
develop preeclampsia, exogenous administration of sFlt-1 to
pregnant rats induces some of the symptoms similar to the
preeclamptic phenotype, including hypertension, proteinuria,
and glomerular endotheliosis (Maynard et al., 2003). Similarly,
glomerular endotheliosis and proteinuria can be induced in
non-pregnant mice using antibodies against VEGF (Sugimoto
et al., 2003), or by reducing glomerular VEGF levels by 50%
(Eremina et al., 2003). In addition, administration of sFlt-1
can block VEGF and PlGF-induced microvascular relaxation of
rat renal arterioles in vitro (Maynard et al., 2003). These stud-
ies all demonstrate that abnormal inhibition of endogenous
VEGF activity can induce maternal preeclampsia-like symptoms.
Similarly, administration of a therapeutic VEGF neutralizing
antibody leads to renal pathology which can be replicated in
adult animals by conditional gene targeting (Eremina et al.,
2008). sFlt-treated animals do not develop additional symp-
toms of PE such as hemolysis and thrombocytopenia, seen
in the HELLP syndrome. However, co-administration of sFlt-
1 with sEng ampliﬁes the symptoms, resulting in severe PE
and/or HELLP syndrome, suggesting that these two placenta-
derived factors could act in concert to induce severe preeclampsia
(Venkatesha et al., 2006). We have shown similar synergistic
effects between sFlt-1 and TNF-α. sFlt-1 sensitized endothe-
lial cells to pro-inﬂammatory factors, increasing endothelial
cell activation, as measured by increases in endothelial inter-
cellular adhesion molecule 1 (ICAM1), vascular cell adhesion
molecule 1, endothelin 1 (ET-1), von Willebrand factor and
leukocyte adhesion, and led to reduction of AKT Ser473 and
endothelial nitric oxide synthase (eNOS) Ser1177 phosphoryla-
tion (Cindrova-Davies et al., 2011). The survival of endothe-
lial cells in vivo under non-pathological conditions is critically
dependent on autocrine VEGF signaling. Endothelial speciﬁc
ablation of VEGF results in progressive endothelial degeneration
and sudden death of mutant animals (Lee et al., 2007), whilst
autocrine VEGF is necessary for the survival of hematopoietic
stem cells (Gerber et al., 2002), demonstrating that paracrine
actions of VEGF are not sufﬁcient to maintain the target cells.
Thus, in preeclampsia the elevated circulating sFlt-1 is able to
act in a dominant-negative fashion at the endothelial cell sur-
face, blocking these autocrine signals (Cindrova-Davies et al.,
2011).
LINKING ANTIANGIOGENIC FACTORS WITH ENDOTHELIAL
DYSFUNCTION
Maternal symptoms of preeclampsia present as a consequence
of maternal endothelial cell dysfunction, not due to dysregula-
tion of maternal angiogenesis. Secretion of antiangiogenic factors
from the placenta can adversely affect maternal endothelial func-
tion. The higher relative concentrations of the antiangiogenic
factors are thought to potentiate vascular endothelial cell injury
in the liver, kidney, brain, and the placenta itself, and thus trig-
ger the symptoms of preeclampsia. Placental oxidative stress due
to malperfusion is now commonly considered as the underlying
source for antiangiogenic factors which are at the root of the
symptomatic phase of preeclampsia. However, the mechanism
linking the angiogenic imbalance with endothelial dysfunction
is still under investigation. Endothelin-1 (ET-1), a potent vaso-
constrictor and pressor agent involved in the regulation of blood
pressure, has been shown to play a crucial role in the develop-
ment of hypertension in experimental animal models of placental
hypoxia/ischemia (George and Granger, 2011). Long-term infu-
sion of ET-1 into sheep also induced preeclampsia-like symptoms,
i.e., hypertension, proteinuria, and decreased uteroplacental blood
ﬂow (Greenberg et al., 1997). In addition, several studies have
reported elevated levels of plasma ET-1 in preeclamptic pregnant
women, compared to controls (Taylor et al., 1990; Nova et al., 1991;
Baksu et al., 2005).
The expression of VEGF and sFlt-1 can be regulated by
the hypoxia-inducible factor-1 (HIF-1), a key component of a
widely operative transcriptional response activated by hypoxia.
Hypoxia increases HIF-1α stability, but it can also be up-regulated
under non-hypoxic conditions by inﬂammatory cytokines or
microtubule-depolymerising agents involving the NF-κB pathway
(Jung et al., 2003). HIF-1-mediated sFlt-1 secretion can by induced
in placental explants by hypoxia or hypoxia-reoxygenation (HR)
in vitro (Achmad et al., 1997; Nagamatsu et al., 2004; Cindrova-
Davies et al., 2007; Cudmore et al., 2007; Cindrova-Davies, 2009).
These in vitro effects can be blocked by anti-oxidant vitamins,
inhibitors of the p38 MAPK and NF-κB pathways, and by over-
expression of the heme oxygenase (HO-1)/CO, suggesting the
involvement of oxidative stress, NF-κB, p38 signaling and HO-
1 in sFlt-1 and HIF-1α regulation (Cindrova-Davies, 2009). sEng
inhibits TGF-β signaling in the vasculature, which includes effects
on activation of eNOS and vasodilation. It has been postu-
lated that increased circulating levels of sFlt-1 lead to reduction
of VEGF and NOS, thus reducing NO production. Adminis-
tration of sFlt-1 to pregnant rats induced hypertension and
signiﬁcantly increased the production of prepro-ET message lev-
els in the renal cortex. The hypertensive response could be
abolished with coadministration of an ETA antagonist (Mur-
phy et al., 2010). Administration of sFlt-1 to pregnant animals
thus impairs VEGF-R2-mediated NO production, reducing NO
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bioavailability, thereby increasing systemic peripheral resistance
and inducing hypertension. NO bioavailability may be further
reduced by increased oxidative stress, and leads to enhanced ET-1
production and increased blood pressure (George and Granger,
2011).
Differences have been reported in the oxygen sensing abil-
ity of early vs. late onset PE. Rolfo et al. (2010) reported a
disruption of oxygen sensing in early onset disease but not in
the late-onset, and they speculate this contributes to decreased
HIF-1α hydroxylation and breakdown, leading to its accumu-
lation in early onset PE (Rolfo et al., 2010). As mentioned
previously, hypoxia is disputed by many as the leading cause
of placental pathologies. Instead, ischemia-reperfusion (Hung
et al., 2002; Burton et al., 2009) or hyperoxia (Kingdom and
Kaufmann, 1997; Huppertz et al., 2014) have been proposed
as the underlying etiological factors in PE. Nevertheless, all
these conditions lead to generation of reactive oxygen species
(ROS), which can increase HIF-1α levels and stability. In addi-
tion, HIF-1α can be stabilized under normoxic conditions by
other mechanisms such as components of the immune system,
especially inﬂammatory cytokines, and hormones (Zhou and
Brüne, 2006). Preeclampsia is a condition of excessive inﬂamma-
tory responses mediated by syncytiotrophoblast microparticles,
pathogens and DAMPs (damage-associated molecular pattern),
which activate toll-like receptors (TLR) and through binding
to immune cells promote persistent inﬂammatory conditions in
this syndrome (Laresgoiti-Servitje, 2010). TNF-α can promote
the release of sFlt-1 (Parrish et al., 2010), and similarly, AT1
autoantibodies can promote the secretion of sEng and sFlt-1
through TNF-α-mediated mechanisms (Zhou et al., 2008; Irani
et al., 2010).
OXIDATIVE STRESS AND ANTIOXIDANTS
Strong evidence exists that generation of placental oxidative stress
is a key intermediary event in the pathology of preeclampsia
(Hubel, 1999; Redman and Sargent, 2000; Burton and Jauniaux,
2004). It is thought that deﬁcient conversion of the uterine spiral
arteries and subsequent impaired perfusion of the placenta pro-
vides the initiating insult (Brosens et al., 2002). In early gestationof
normal pregnancy, the spiral arteries undergo substantial remod-
eling by invasive extravillous trophoblasts, which penetrate into
the myometrium and convert muscular spiral arteries into ﬂaccid
tubes with no muscularis or elastic lamina, capable of supplying
the hugely expanded blood ﬂow of the third trimester placenta.
In contrast, the remodeling is minimal in PE, only affecting the
decidual segments of the spiral arteries, which retain their high-
resistance (Brosens et al., 2002). Maternal blood thus enters the
intervillous space at a higher pressure and a faster rate, in a pulsatile
jet-like manner, exposing placental villi to ﬂuctuating oxygen con-
centrations, which contributes to the ischemia-reperfusion (I/R)
type injury of the placenta (Jauniaux et al., 1994, 1995; Burton and
Hung, 2003). The resulting oxidative stress is thought to induce
the placenta to release a mixture of factors, including inﬂam-
matory cytokines, antiangiogenic factors, and apoptotic debris,
which culminates in an enhancedmaternal inﬂammatory response
and endothelial dysfunction (Roberts, 1998; Redman and Sargent,
2005).
The role of oxidative stress in mediating PE pathophysiol-
ogy is supported by reports of signiﬁcantly decreased levels of
antioxidant vitamins C, A, E, β-carotene, glutathione levels, and
iron-binding capacity in the maternal circulation of women with
preeclampsia. There is also evidence of diminished superox-
ide dismutase (SOD) levels and activity in the maternal and
placental compartments of preeclamptic women, indicative of
decreased total antioxidant protective capacity in preeclampsia
(Walsh, 1998). In the experimental model of reduced uterine
perfusion pressure (RUPP) of placental ischemia-induced hyper-
tension, treatment with vitamins C and E did not decrease
blood pressure, while the SOD mimetic Tempol attenuated RUPP
hypertension. Interestingly, treatment with an NADP(H) oxi-
dase inhibitor attenuated but did not normalize hypertension,
suggesting other ROS-generating pathways (Gilbert et al., 2008;
Sedeek et al., 2008). Challenging placental explants with hypoxia-
reoxygenation (HR) or hypoxia in vitro induced sFlt-1 expression
via HIF-1α upregulation (Ahmad and Ahmed, 2004; Nagamatsu
et al., 2004; Cindrova-Davies et al., 2007). We showed that admin-
istration of vitamins C and E can block HR-mediated sFlt-1
secretion, via inhibition of p38 and NF-κB signaling pathways
(Cindrova-Davies et al., 2007; Cindrova-Davies, 2009). Simi-
larly, the in vivo challenge of labor results in increased oxidative
stress, and increased expression of HIF-1 α, sFlt-1 and VEGF
(Cindrova-Davies et al., 2007).
The regulatory role of oxidative stress in the I/R-type injury
in preeclampsia and cardiovascular disease, together with encour-
aging in vitro and ex vivo data introduced the hypothesis that
antioxidant vitaminsmight play an important role in the treatment
of the ischemic disease pathology. However, despite encourag-
ing in vitro data and cohort trials, clinical trials aimed to treat
women at risk of preeclampsia with vitamins C and E (Poston
et al., 2006; Rumbold et al., 2006) showed no reduction in the
incidence of the disease. These results are disappointing. Peri-
conceptional use of vitamins in women is associated with lower
rates of severe preterm births and extreme SGA, which seems to
suggest that vitamin use might be effective during conception
and early pregnancy (Catov et al., 2007), and that the clinical
trial administration of vitamins occurred too late in pregnancy
to reverse already established disease pathology. The outcome
could also be affected by the composition of natural vs. syn-
thetic vitamins, as evidence exists that healthy Mediterranean diet
lowers the incidence of preterm birth (Haugen et al., 2008) and
coronary heart disease (Aravanis et al., 1970). Synergy between
different mediators may also be important in disease treatment.
Recent clinical trial found that whilst antioxidant vitamins alone
did not have a protective effect for prevention of PE, there was
a synergistic effect between L-arginine and vitamin C, reduc-
ing the incidence of PE in these patients (Vadillo-Ortega et al.,
2011). Endogenous NADPH oxidase and manganese SOD are
required to maintain VEGF signaling and vascular homeostasis
(Abid et al., 2001, 2007). Interestingly, despite no effect of the
vitamin trials on lowering the incidence of preeclampsia, antiox-
idant supplementation led to a signiﬁcant decrease in the plasma
concentration of sFlt-1 and an increase in the plasma concentra-
tion of PlGF (Poston et al., 2011), matching our in vitro ﬁndings
and conﬁrming the beneﬁcial effect of antioxidants on VEGF
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signaling. Antioxidant vitamins could interfere with the nor-
mal physiological roles of VEGF and there seems to be a scope
for potential use of antioxidants in preventing or ameliorating
preeclampsia.
NO SUPPLEMENTATION
Endothelium plays a crucial role in regulating vascular tone. In
preeclamptic patients, endothelial activation is manifested by
increased expression of markers of endothelial activation, includ-
ingVCAM, endothelin, vonWillebrand Factor, and thrombomod-
ulin (Mutter andKarumanchi, 2008). Nitric oxide (NO),hydrogen
sulﬁde (H2S), and carbon monoxide (CO) are three gaseous
vasodilators that maintain the vascular tone. NO release from
endothelial cells counter-balances the vasoconstriction produced
by the sympathetic nervous system and the renin–angiotensin
system. In addition, NO exerts many vasoprotective and anti-
atherosclerotic properties, including protection from thrombosis,
reduction of adhesion molecule expression and leukocyte adhe-
sion. NO is produced by nitric oxide synthase (NOS), using
L-arginine as a substrate. In addition, endogenously produced
methylated amino acids such as asymmetric dimethylarginine
(ADMA) can act as competitive inhibitors, and their secretion
is increased in patients with cardiovascular disease and renal
failure (Schnabel et al., 2005), as well as in women with high resis-
tance placental circulation at risk of preeclampsia, IUGR, or both
(Savvidou et al., 2003).
NO formation was found to be impaired in women with
preeclampsia and gestational hypertension, compared to healthy
pregnant controls. A negative correlation exists between plasma
nitrite levels and sFlt-1 and sEng, suggesting an inhibitory effect
of the angiogenic factors on NO formation (Sandrim et al., 2008).
Given the important role of NO in the pathophysiology of
preeclampsia, much research has concentrated on targeting the
NOpathway as a potential therapy for preeclampsia. These include
organic nitrates and S-nitrosothiols (e.g., S-nitrosoglutathione),
L-arginine, inhibitors of cGMP breakdown (e.g., sildenaﬁl), and
other novel inhibitors of NO donor metabolism. This topic has
been reviewed extensively by Johal et al. (2013). S-nitroglutathione
(GSNO), endogenous S-nitrosothiol found ubiquitously in tis-
sue, has been infused in women with preeclampsia and it
has been shown to target not only the endothelial dysfunc-
tion, but also reduce platelet aggregation and activation, reduce
sEng, and improve utero-placental perfusion with no adverse
side effects, making it a good potential candidate for PE ther-
apy (de Belder et al., 1995; Lees et al., 1996; Johal et al., 2013).
The effects of supplementation with NO precursor, L-arginine,
have been studied in several clinical trials. A recent random-
ized control trial of high risk pregnant women showed that
dietary supplementation with a combination of L-arginine and
antioxidants was associated with a signiﬁcant reduction in the
incidence of preeclampsia, compared to antioxidants alone or
placebo prevention of preeclampsia (Vadillo-Ortega et al., 2011).
These are encouraging results although they have to be inter-
preted with caution, given that the effects of L-arginine alone
were not studied, and as such it is difﬁcult to dissect out the
relative contributions of L-arginine and antioxidants in reduc-
ing the incidence of the disease. These encouraging results were
echoed in a recent systematic review of randomized trials focused
on the role of L-arginine in the prevention of preeclampsia
(Dorniak-Wall et al., 2014). The authors analyzed 7 random-
ized controlled trials testing the effects of L-arginine in pregnant
women, and they reported L-arginine supplementation was asso-
ciated with a signiﬁcant reduction in the risk of preeclampsia in
pregnant women with either established hypertension or who
were considered at risk of preeclampsia (Dorniak-Wall et al.,
2014).
The mechanism of the beneﬁcial effect of L-arginine sup-
plementation has been studied in pregnant rats in whom
preeclampsia-like phenotype was induced with sFlt-1 adminis-
tration (Murphy et al., 2011). sFlt-1 infusion into pregnant rats
induced hypertension associated with reductions in circulating
levels of VEGF, signiﬁcant proteinuria, and endothelial dysfunc-
tion, as marked by a 3.5% increase in renal cortical pro-ET
mRNA expression (Maynard et al., 2005; Gilbert et al., 2007; Mur-
phy et al., 2010, 2011). Administration of L-arginine decreased
sFlt-1 hypertension but had no effect on the blood pressure
response in non-pregnant rats. In addition, L-arginine abolished
the sFlt-mediated expression of renal cortical prepro-ET, suggest-
ing that a reduction in NO synthesis may play an important role
in the enhanced ET-1 production in response to sFlt-1 hyper-
tension in pregnant rats (Murphy et al., 2011). These data are
supported by previous studies, which showed a link between
reducedNOproduction and enhancedET-1production (Kourem-
banas et al., 1993; Edwards et al., 1996). It has been postulated that
increased circulating levels of sFlt-1 lead to reduction of VEGF
and NOS, thus reducing NO production (George and Granger,
2011).
ER STRESS AND ER STRESS INHIBITORS
Endoplasmic reticulum (ER) processes all secreted proteins, facili-
tating folding and post-translationalmodiﬁcations. Accumulation
of misfolded proteins leads to activation of ER stress response
pathways, collectively known as the Unfolded Protein Response
(UPR). The aim of the UPR is to restore homeostasis by inhibit-
ing translation of non-essential proteins, increasing the capacity
of the chaperone and folding machinery, and stimulating degra-
dation of misfolded proteins. Failure of the mechanism results
in activation of apoptotic pathways. ER stress is a major reg-
ulator of cell homeostasis (Xu et al., 2005; Cullinan and Diehl,
2006; Yoshida, 2007). The UPR is initiated by three transmem-
brane sensors normally held inactive by binding of the principal
ER chaperone, GRP78. These sensors are PERK (PRKR-like ER
kinase) that phosphorylates eukaryotic initiation factor 2α (eIF2α)
to inhibit translation, ATF6 (activating transcription factor 6)
and IRE1 (inositol-requiring enzyme 1). ATF6 is cleaved to pro-
duce an active transcription factor, while IRE1 splices the mRNA
encoding XBP-1 (X-box binding protein-1) to produce a second
transcription factor. These factors have overlapping functions,
and both upregulate ER chaperone proteins, including GRP78,
and degradation pathways (Xu et al., 2005; Cullinan and Diehl,
2006; Yoshida, 2007). In addition, ER stress can generate and
accumulate ROS, thus promoting oxidative stress. Activation of
the NF-κB pathway links increased oxidative stress, ER stress
and inﬂammation. NF-κB can be activated by an increase in
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ER stress via PERK-eIF2α activation or IRE1α autophosphory-
lation. This effect can be blocked by both calcium chelators
and antioxidants, suggesting NF-κB activation could be a result
of the oxidative stress arising from excessive protein folding
and/or ER-stress mediated Ca2+ leakage (Zhang and Kaufman,
2008).
Disorders of ER function are recognized to underlie many
diverse pathologies, including diabetes and neurodegenerative
diseases, and therapeutic interventions targeting it are being
devised (Hetz et al., 2013). ER stress also seems instrumental
in the pathophysiology of preeclampsia and IUGR (Yung et al.,
2008, 2012). Use of ER chaperones proved a beneﬁcial therapy
for treatment of type 2 diabetes as it restored systemic insulin
sensitivity, normalized hyperglycemia, resolved fatty liver dis-
ease, and enhanced insulin action in various tissues (Ozcan et al.,
2006). Similarities exist between preeclampsia and metabolic
syndrome, including dyslipidemia, inﬂammation, insulin resis-
tance, oxidative stress and ER stress. We have demonstrated an
increased expression of ET-1 and sFlt-1 in HR-treated placental
explants (Cindrova-Davies et al., 2007; Cindrova-Davies, 2009).
Conditioned medium from HR explants induced ER stress in
JEG-3 cells, which was abolished by an ET-1 neutralizing anti-
body (Jain et al., 2012). Administration of ER chaperone TUDCA
to placental explants challenged with HR reduced the levels of
endothelin-1 (ET-1) in these explants, and it reduced the protein
levels of sFlt-1 (unpublished observations). These data suggest
that restoring ER function could also offer a therapeutic ben-
eﬁt for the treatment of preeclampsia. The ER chaperones are
endogenously produced bile salts ursodeoxycholic acid (UDCA,
TUDCA). The chaperones have excellent in vivo safety pro-
ﬁles and their use has been approved in clinical trials for the
treatment of urea-cycle disorders, thalassemia and cystic ﬁbro-
sis (Ozcan et al., 2006), and they are currently used to treat
intrahepatic cholestasis of pregnancy (Geenes and Williamson,
2009).
STATINS
Preeclampsia has been associated with dyslipidemia, and there
is evidence of increased antibodies for oxidized form of LDL in
patients with preeclampsia, which is consistent with oxidative
stress, and it is analogous to changes described in atheroscle-
rosis (Branch et al., 1994). Although preeclampsia is unique to
pregnancy, there are many biological and pathological similarities,
as well as risk factors (e.g., hypertension, obesity, dyslipidemia,
diabetes, etc.) with adult cardiovascular disease. The mechanism
underlying both atherosclerosis (Hansson, 2005) and preeclamp-
sia (Roberts and Cooper, 2001; Redman and Sargent, 2005) is
initiated by underlying endothelial dysfunction and inﬂammation,
which lead to disease progression and manifestation. Pregnancy is
often viewed as a stress test, and preeclampsia an early manifesta-
tion of CV disease. In fact, women who develop preeclampsia
have a two- to threefold risk of hypertension, ischemic stroke
and heart disease in later life (van Pampus and Aarnoudse, 2005;
McDonald et al., 2008), and the risk is further increased with the
severity of the disease, and early manifestation before 34 weeks
gestation (Mongraw-Chafﬁn et al., 2010). Given the analogies
between the two diseases, some remedies and treatments used
to prevent and treat cardiovascular disease have been tested in
preeclampsia.
Natural and synthetic statins (or 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase inhibitors) are the most
commonly prescribed classes of medication worldwide, used in
primary and secondary prevention of cardiovascular mortality
and other cardiovascular events through lipid-lowering remedy,
as well as many pleiotropic effects, including endothelial protec-
tion, antioxidant properties, anti-inﬂammatory, antithrombotic
and proangiogenic effects (Costantine and Cleary, 2013; Girardi,
2014). The beneﬁcial effects of statins in the treatment of cardio-
vascular disease have been conﬁrmed by recent meta-analysis of
individual data from 90,000 individuals in 14 randomized trials
of statin therapy vs. placebo, called the Cholesterol Treatment
Trialists’ (CTT) Collaboration (Baigent et al., 2005). The CTT
concluded that statin therapy can safely reduce the 5-year inci-
dence of major coronary events, coronary revascularization, and
stroke by about one ﬁfth permmol/L reduction in LDL cholesterol,
largely irrespective of the initial lipid proﬁle or other presenting
characteristics (Baigent et al., 2005).
The effect of pravastatin administration in pregnancy has been
tested in many rodent models of preeclampsia. Treatment with
pravastatin signiﬁcantly reduced maternal sFlt-1 levels, lowered
blood pressure, improved the vascular proﬁle, and prevented
kidney injury (Ahmed et al., 2010; Costantine et al., 2010; Fox
et al., 2011; Kumasawa et al., 2011; Saad et al., 2014). In addition,
pravastatin also prevented the incidence of intrauterine growth
restriction, without any adverse effects on pregnancy. In a mouse
model of preeclampsia using placenta-speciﬁc lentiviral vector
expression of sFlt-1, Kumasawa et al. elegantly demonstrated
that pravastatin administration decreased sFlt-1 but importantly
increased PlGF, thus restoring the angiogenic balance (Kuma-
sawa et al., 2011). Pravastatin effects could be reproduced by
administration of PlGF, which reduced sFlt-1 levels, amelio-
rated hypertension, glomerular endotheliosis, and proteinuria
in the mice, suggesting that the beneﬁcial effect of pravas-
tatin on improving preeclampsia-like symptoms is mediated by
increasing PlGF levels, which counteracts sFlt-1-mediated effects
(Kumasawa et al., 2011). In addition, statins also exert protective
effects on the endothelium and ameliorate preeclampsia symp-
toms by increasing the release of vasodilators NO (Redecha et al.,
2009; Fox et al., 2011) and CO (Cudmore et al., 2007; Muchova
et al., 2007). Pravastatin treatment of mice destined to develop
preeclampsia using sFlt-1 overexpression increased eNOS protein
expression in the vasculature (Fox et al., 2011), whilst pravas-
tatin improved pregnancy outcome by increasing plasma NO
levels in CBAxDBA/2 mice destined to develop recurrent mis-
carriage and IUGR (Redecha et al., 2009). Treatment of mice
with statins resulted in increased HO-1 activity and increased
CO release from tissues, as well as increased levels of plasma
antioxidants (Muchova et al., 2007). Statins also induced the
expression of HO-1 and inhibited sFlt-1 secretion in placental
explants (Cudmore et al., 2007). These studies provide further evi-
dence of a pleiotropic role of pravastatin in preventing the vascular
dysfunction.
Given the encouraging evidence of the beneﬁcial effects of
statins on the prevention of cardiovascular disease in humans
www.frontiersin.org May 2014 | Volume 5 | Article 119 | 7
Cindrova-Davies New therapeutic targets for preeclampsia
and of preeclampsia in animal models, the ability of pravas-
tatin to restore angiogenic balance is currently being tested in
the ﬁrst randomized placebo controlled StAmP trial (Statins to
ameliorate early onset preeclampsia) in the UK. The aim of the
trial is to establish if pravastatin can lead to a signiﬁcant reduc-
tion in circulating antiangiogenic factors and alleviate the severity
of early onset preeclampsia. The pleiotropic anti-inﬂammatory,
anti-thrombotic, antioxidant and vascular protective effects sug-
gest that statins might be a good therapeutic option to prevent
preeclampsia.
FUTURE DIRECTIONS – H2S DONORS
Endogenous H2S plays an important role in regulating physiolog-
ical processes such as blood ﬂow, vasodilation, arterial diameter,
and leukocyte adhesion (Wang, 2009). Endogenous production
is catalyzed by cystathionine β-synthase (CBS) and cystathion-
ine γ-lyase (CSE). H2S is produced in the cardiovascular system
by CSE, using cysteine as a substrate. It acts as a vasodilator,
being able to hyperpolarize and relax SMCs by opening KATP
channels (Zhao et al., 2001). Unlike NO and CO, which mediate
vasorelaxation largely by cGMP pathway activation, the vasorelax-
ant effect of H2S is independent of cGMP pathway (Zhao et al.,
2001). In addition, NO effects depend largely on the endothelial
function integrity, whereas H2S is an endothelium-independent
vasodilator and exerts its direct effect on SMCs. CSE knock-
out mice have markedly reduced serum H2S levels, which results
in pronounced hypertension and diminished vasodilation, pro-
viding direct evidence that H2S is a potent vasodilator that can
inﬂuence blood pressure (Yang et al., 2008). Similarly, genetic
deﬁciency of CBS leads to homocysteinemia, which is associated
with endothelial dysfunction and hypertension (Miles and Kraus,
2004). We reported reduced CSE expression in IUGR cases, as
well as PE cases that were accompanied by abnormal UA Doppler
proﬁles, and this could be recapitulated by subjecting placental
explants to HR. In addition, we demonstrated a potent vasodila-
tory effect of an H2S donor in perfused placentas, capable of KATP
dependent-reduction of placental vascular resistance. Reduced
bioavailability of H2S may thus be implicated in placental vaso-
constriction (Cindrova-Davies et al., 2013). In addition to being
a potent vasodilator, many animal studies also showed a protec-
tive role of H2S donors against ischemia-reperfusion injury and
inﬂammation (Bos et al., 2009, 2013; Sodha et al., 2009). The
pro-survival pathways AKT, PKC, and ERK1/2 have been iden-
tiﬁed as H2S targets conferring its anti-apoptotic effects during
reperfusion injury (Hu et al., 2008; Yong et al., 2008). Additionally,
H2S can promote direct anti-apoptotic signaling during ischemia-
reperfusion by activating eNOS and thus inducing NO (Yong et al.,
2008), andH2SpromotesDNAbinding and transcriptional activa-
tion of anti-apoptotic genes regulated by NF-κB (Sen et al., 2012).
The antioxidant properties of H2S can be mediated via two dis-
tinct mechanisms; by acting as a direct scavenger of ROS and by
up-regulating antioxidant defenses. H2S may up-regulate endoge-
nous antioxidants through a nuclear factor E2-related factor-2
(Nrf2; Calvert et al., 2009). Nrf2 binds the antioxidant respon-
sive element (ARE) found in the promoter region of antioxidant
genes, including heme oxygenase-1 (HO-1), thioredoxin, thiore-
doxin reductase, glutathione reductase, glutathione peroxidase
(GPx), glutathione S-transferase (GSS), and catalase and is thus
an important factor in controlling cardiac cellular susceptibil-
ity to reactive oxygen and nitrogen species-induced cytotoxicity
(Zhu et al., 2005). Garlic oil can also promote Nrf-2 activation,
further supporting the role for Nrf2 as the mediator of H2S-
induced antioxidant effects (Fisher et al., 2007). Additionally, CSE
expression appears to be a critical component of the cytopro-
tective ATF4 transcriptional response; CSE deﬁciency increases
sensitivity to apoptosis induced by ER stressors and homocys-
teine, indicating the importance of GSH up-regulation through
the transsulfuration pathway to promote survival (Dickhout et al.,
2012). H2S also exerts important proangiogenic effects (Cai et al.,
2007; Wang et al., 2010; Bir et al., 2012; Holwerda et al., 2014).
H2S promotes proliferation, adhesion, migration and tube-like
structure formation of endothelial cells in vitro via AKT path-
way phosphorylation. It also stimulates angiogenesis in vivo at
physiologically relevant doses (Cai et al., 2007). NO-H2S cross-
talk seems critical in mediating these effects (Bir et al., 2012;
Coletta et al., 2012). H2S therapy restores blood ﬂow to ischemic
tissues in a NO-dependent manner, by stimulating NOS expres-
sion and HIF-1α and VEGF expression and activity (Bir et al.,
2012).
Consistent with these roles of H2S, the consumption of garlic
is negatively correlated with the progression of CV disease, and
causes a lower incidence of hypertension, enhances antioxidants
and inhibits platelet aggregation (Banerjee and Maulik, 2002). It
has been shown that the biological production of H2S from garlic-
derived organic polysulﬁdes mediates the major beneﬁcial effects
of garlic-rich diets, speciﬁcally on CV disease and more broadly on
overall health (Benavides et al., 2007). In animalmodels of hypoxic
pulmonary hypertension, H2S could reverse structural remodel-
ing changes in pulmonary vessels of rats exposed to chronic HR
(Hongfang et al., 2006). H2S therapy also protected against acute
myocardial ischemia/reperfusion (Calvert et al., 2009), and atten-
uated cardiac dysfunction following heart failure (Kondo et al.,
2013; Polhemus et al., 2013). Recent animal studies have focused
on the use of “medical food,” i.e., drugs derived from natural
sources such as garlic, as a cardioprotective therapy for heart
failure. These include diallyl trisulﬁde (DATS; Polhemus et al.,
2013), a long acting H2S donor derived from garlic, and sulfur-
releasing “medical food” SG-1002 (Kondo et al., 2013), which
is currently in clinical trials. Similar results have been reported
in the placental ﬁeld recently. Holwerda et al. (2014) evaluated
the therapeutic effect of an H2S donor in an animal model of
sFlt-induced hypertension. They reported a signiﬁcant reduc-
tion in blood pressure, and proteinuria, as well as concomitant
reduction in sFlt-1 levels and increase in free maternal VEGF
concentrations in the treated group of animals (Holwerda et al.,
2014). Wang et al. (2013) demonstrated that CSE enzyme inhi-
bition in pregnant mice induced hypertension, increased sFlt-1
and sEng levels, caused placental abnormalities and compromised
fetal growth. H2S donor therapy reduced the levels of the antian-
giogenic factors and restored fetal growth, adding further weight
to the evidence that a dysfunctional CSE/H2S pathway may con-
tribute to the pathogenesis of preeclampsia (Wang et al., 2013), and
that H2S donor therapy could have beneﬁcial effects on prevention
of preeclampsia.
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FIGURE 1 | Proposed pathways contributing to the maternal syndrome
of preeclampsia and the mechanism of action of antioxidants, ER
chaperones, NO, and H2S donors and statins. Deﬁcient conversion of
spiral arteries leads to ﬂuctuations in O2 concentration and triggers
ischemia-reperfusion type injury of the placenta and consequent oxidative
stress and ER stress. ROS activate various stress pathways, including
proapoptotic p38 and inﬂammatory NF-κB pathway. These pathways promote
increased shedding of microparticles, anti-angionenic factors and
inﬂammatory cytokines, which lead to development of the peripheral
maternal symptoms. Antioxidants, ER chaperones, NO and H2S donors and
statins all display pleitrophic effects, targeting inﬂammatory, stress,
antioxidant pathways, as well as VEGF and NO signaling.
CONCLUDING REMARKS
Therapeutic interventions to treat preeclampsia remain largely
experimental and there is no established remedy for the treatment
of this multifactorial disease. This review concentrated on the evi-
dence for the therapeutic potential of antioxidants, ER chaperones,
NO and H2S donors, and statins. Mechanistic effects of these com-
pounds on the signaling pathways involved in the pathophysiology
of preeclampsia, are summarized in Figure 1. Antioxidants, ER
chaperones, NO donors, statins and H2S donors display pleitropic
antioxidant, anti-inﬂammatory, and pro-angiogenic effects in ani-
mal and in vitro studies. Encouraging clinical evidence exists for
the use of NO donors, and a clinical trial is currently underway
testing the effect of statins in treatment of preeclampsia. Although
clinical trials on the use of antioxidant vitamins in pregnancy
proved largely unsuccessful, the scope for their use still exists given
the beneﬁcial cardioprotective effects of antioxidant-rich Mediter-
ranean diet, periconceptual vitamin use and the synergistic effect
of vitamin C and L-arginine. H2S recently emerged as a novel ther-
apeutic agent for cardiovascular disease and its effects are being
tested.
ACKNOWLEDGMENTS
I would like to acknowledge the support of the Wellcome Trust
(084804/2/08/Z) and the guidance and mentoring of Professors
Graham J. Burton and D. Stephen Charnock-Jones.
REFERENCES
Abid,M. R., Spokes, K. C., Shih, S. C., andAird,W. C. (2007). NADPH oxidase activ-
ity selectively modulates vascular endothelial growth factor signaling pathways.
J. Biol. Chem. 282, 35373–35385. doi: 10.1074/jbc.M702175200
Abid, M. R., Tsai, J. C., Spokes, K. C., Deshpande, S. S., Irani, K., and
Aird, W. C. (2001). Vascular endothelial growth factor induces manganese-
superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH
oxidase-dependent mechanism. FASEB J. 15, 2548–2550.
Achmad, T., Winterscheidt, A., Lindemann, C., and Rao, G. S. (1997). Oxidized
low density lipoprotein acts on endothelial cells in culture to enhance endothelin
secretion and monocyte migration. Methods Find. Exp. Clin. Pharmacol. 19,
153–159.
Ahmad, S., and Ahmed, A. (2004). Elevated placental soluble vascular endothelial
growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95,
884–891.
Ahmed, A., Singh, J., Khan, Y., Seshan, S. V., and Girard, G. (2010). A new
mouse model to explore therapies for preeclampsia. PLoS ONE 5:e13663. doi:
10.1371/journal.pone.0013663
American College of Obstetricians and Gynecologists (2013). Hypertension in
pregnancy. DNLM: 1. Hypertension, Pregnancy-Induced-Practice Guideline. Wash-
ington: LoCCiP Data.
Aravanis, C., Corcondilas, A., Dontas, A. S., Lekos, D., and Keys, A. (1970). Coro-
nary heart disease in seven countries. IX. The Greek islands of Crete and Corfu.
Circulation 41(Suppl. 4), I88–I100.
Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., et al.
(2005). Efﬁcacy and safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet
366, 1267–1278. doi: 10.1016/S0140-6736(05)67394-1
Baksu, B.,Davas, I., Baksu,A.,Akyol,A., andGulbaba,G. (2005). Plasmanitric oxide,
endothelin-1 and urinary nitric oxide and cyclic guanosinemonophosphate levels
www.frontiersin.org May 2014 | Volume 5 | Article 119 | 9
Cindrova-Davies New therapeutic targets for preeclampsia
in hypertensive pregnant women. Int. J. Gynaecol. Obstet. 90, 112–117. doi:
10.1016/j.ijgo.2005.04.018
Banerjee, S. K., and Maulik, S. K. (2002). Effect of garlic on cardiovascular disorders:
a review. Nutr. J. 1, 4. doi: 10.1186/1475-2891-1-4
Benavides, G. A., Squadrito, G. L., Mills, R. W., Patel, H. D., Isbell, T. S., Patel, R.
P., et al. (2007). Hydrogen sulﬁde mediates the vasoactivity of garlic. Proc. Natl.
Acad. Sci. U.S.A. 104, 17977–17982. doi: 10.1073/pnas.0705710104
Bir, S. C., Kolluru, G. K., McCarthy, P., Shen, X., Pardue, S., Pattillo, C. B., et al.
(2012). Hydrogen sulﬁde stimulates ischemic vascular remodeling through nitric
oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-
1alpha and vascular endothelial growth factor-dependent angiogenesis. J. Am.
Heart Assoc. 1, e004093. doi: 10.1161/JAHA.112.004093
Bos, E. M., Leuvenink, H. G., Snijder, P. M., Kloosterhuis, N. J., Hillebrands, J.
L., Leemans, J. C., et al. (2009). Hydrogen sulﬁde-induced hypometabolism pre-
vents renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 20, 1901–1905. doi:
10.1681/ASN.2008121269
Bos, E. M., Wang, R., Snijder, P. M., Boersema, M., Damman, J., Fu, M., et al.
(2013). Cystathionine gamma-lyase protects against renal ischemia/reperfusion
by modulating oxidative stress. J. Am. Soc. Nephrol. 24, 759–770. doi:
10.1681/ASN.2012030268
Branch, D. W., Mitchell, M. D., Miller, E., Palinski, W., and Witztum, J. L. (1994).
Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet
343, 645–646. doi: 10.1016/S0140-6736(94)92639-5
Brosens, J. J., Pijnenborg, R., and Brosens, I. A. (2002). The myometrial junc-
tional zone spiral arteries in normal and abnormal pregnancies: a review of
the literature. Am. J. Obstet. Gynecol. 187, 1416–1423. doi: 10.1067/mob.2002.
127305
Burton, G. J., and Hung, T.-H. (2003). Hypoxia-reoxygenation: a potential source of
placental oxidative stress in normal pregnancy and preeclampsia. Fetal Maternal
Med. Rev. 14, 97–117. doi: 10.1017/S0965539503001049
Burton, G. J., and Jauniaux, E. (2004). Placental oxidative stress: from
miscarriage to preeclampsia. J. Soc. Gynecol. Investig. 11, 342–352. doi:
10.1016/j.jsgi.2004.03.003
Burton, G. J., Woods, A. W., Jauniaux, E., and Kingdom, J. C. (2009). Rheological
and physiological consequences of conversion of the maternal spiral arteries for
uteroplacental blood ﬂow during human pregnancy. Placenta 30, 473–482. doi:
10.1016/j.placenta.2009.02.009
Cai, W. J., Woods, A. W., Jauniaux, E., and Kingdom, J. C. (2007). The novel
proangiogenic effect of hydrogen sulﬁde is dependent on Akt phosphorylation.
Cardiovasc. Res. 76, 29–40. doi: 10.1016/j.cardiores.2007.05.026
Calvert, J. W., Jha, S., Gundewar, S., Elrod, J. W., Ramachandran, A., Pattillo, C. B.,
et al. (2009). Hydrogen sulﬁde mediates cardioprotection through Nrf2 signaling.
Circ. Res. 105, 365–374. doi: 10.1161/CIRCRESAHA.109.199919
Catov, J. M., Bodnar, L. M., Ness, R. B., Markovic, N., and Roberts, J. M.
(2007). Association of periconceptional multivitamin use and risk of preterm
or small-for-gestational-age births. Am. J. Epidemiol. 166, 296–303. doi:
10.1093/aje/kwm071
Chaiworapongsa, T., Romero, R., Kim, Y. M., Kim, G. J., Kim, M. R., Espinoza, J.,
et al. (2005). Plasma soluble vascular endothelial growth factor receptor-1 con-
centration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern.
Fetal Neonatal. Med. 17, 3–18. doi: 10.1080/14767050400028816
Charnock-Jones, D. S., Kaufmann, P., and Mayhew, T. M. (2004). Aspects of human
fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta
25, 103–113. doi: 10.1016/j.placenta.2003.10.004
Cindrova-Davies, T., Herrera, E. A., Niu, Y., Kingdom, J., Giussani, D. A., and
Burton, G. J. (2013). Reduced cystathionine gamma-lyase and increased miR-21
expression are associated with increased vascular resistance in growth-restricted
pregnancies: hydrogen sulﬁde as a placental vasodilator. Am. J. Pathol. 182, 1448–
1458. doi: 10.1016/j.ajpath.2013.01.001
Cindrova-Davies, T. (2009). Gabor Than Award Lecture 2008: pre-eclampsia - from
placental oxidative stress to maternal endothelial dysfunction. Placenta 30(Suppl.
A), S55–S65. doi: 10.1016/j.placenta.2008.11.020
Cindrova-Davies, T., Sanders, D. A., Burton, G. J., and Charnock-Jones, D. S.
(2011). Soluble, F. L.T1 sensitizes endothelial cells to inﬂammatory cytokines by
antagonizing VEGF receptor-mediated signalling. Cardiovasc. Res. 89, 671–679.
doi: 10.1093/cvr/cvq346
Cindrova-Davies, T., Spasic-Boskovic, O., Jauniaux, E., Charnock-Jones, D. S., and
Burton, G. J. (2007). Nuclear factor-kappa B, p38, and stress-activated protein
kinase mitogen-activated protein kinase signaling pathways regulate proinﬂam-
matory cytokines and apoptosis in human placental explants in response to
oxidative stress: effects of antioxidant vitamins. Am. J. Pathol. 170, 1511–1520.
doi: 10.2353/ajpath.2007.061035
Cindrova-Davies, T., Yung, H. W., Johns, J., Spasic-Boskovic, O., Korolchuk, S.,
Jauniaux, E., et al. (2007). Oxidative stress, gene expression, and protein changes
induced in the human placenta during labor. Am. J. Pathol. 171, 1168–1179. doi:
10.2353/ajpath.2007.070528
Coletta, C., Papapetropoulos, A., Erdelyi, K., Olah, G., Módis, K., Panopoulos,
P., et al. (2012). Hydrogen sulﬁde and nitric oxide are mutually dependent
in the regulation of angiogenesis and endothelium-dependent vasorelaxation.
Proc. Natl. Acad. Sci. U.S.A. 109, 9161–9166. doi: 10.1073/pnas.12029
16109
Costantine, M. M., and Cleary, K. (2013). Pravastatin for the prevention of
preeclampsia in high-risk pregnant women. Obstet. Gynecol. 121(Pt 1), 349–353.
doi: 10.1097/AOG.0b013e31827d8ad5
Costantine,M.M., Tamayo, E., Lu, F., Bytautiene, E., Longo,M.,Hankins,G.D., et al.
(2010). Using pravastatin to improve the vascular reactivity in a mouse model
of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet. Gynecol. 116,
114–120. doi: 10.1097/AOG.0b013e3181e10ebd
Cudmore, M., Ahmad, S., Al-Ani, B., Fujisawa, T., Coxall, H., Chudasama, K.,
et al. (2007). Negative regulation of soluble Flt-1 and soluble endoglin release by
heme oxygenase-1. Circulation 115, 1789–1797. doi: 10.1161/CIRCULATION-
AHA.106.660134
Cullinan, S. B., and Diehl, J. A. (2006). Coordination of ER and oxidative stress
signaling: the PERK/Nrf2 signaling pathway. Int. J. Biochem. Cell Biol. 38, 317–
332. doi: 10.1016/j.biocel.2005.09.018
de Belder, A., Lees, C., Martin, J., Moncada, S., and Campbell, S. (1995). Treat-
ment of HELLP syndrome with nitric oxide donor. Lancet 345, 124–125. doi:
10.1016/S0140-6736(95)90088-8
Dickhout, J. G., Carlisle, R. E., Jerome, D. E., Mohammed-Ali, Z., Jiang, H., Yang,
G. (2012). Integrated stress response modulates cellular redox state via induc-
tion of cystathionine gamma-lyase: cross-talk between integrated stress response
and thiol metabolism. J. Biol. Chem. 287, 7603–7614. doi: 10.1074/jbc.M111.
304576
Dorniak-Wall, T., Grivell, R. M., Dekker, G. A., Hague, W., and Dodd, J. M.
(2014). The role of L-arginine in the prevention and treatment of pre-eclampsia:
a systematic review of randomised trials. J. Hum. Hypertens. 28, 230–235. doi:
10.1038/jhh.2013.100
Edwards, D. L., Arora, C. P., Bui, D. T., and Castro, L. C. (1996). Long-
term nitric oxide blockade in the pregnant rat: effects on blood pressure and
plasma levels of endothelin-1. Am. J. Obstet. Gynecol. 175, 484–488. doi:
10.1016/S0002-9378(96)70166-7
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J.,
et al. (2008). VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J.
Med. 358, 1129–1136. doi: 10.1056/NEJMoa0707330
Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., et al. (2003).
Glomerular-speciﬁc alterations of VEGF-A expression lead to distinct congen-
ital and acquired renal diseases. J. Clin. Invest. 111, 707–716. doi: 10.1172/JCI
17423
Fisher, C. D., Augustine, L. M., Maher, J. M., Nelson, D. M., Slitt, A. L., Klaassen,
C. D., et al. (2007). Induction of drug-metabolizing enzymes by garlic and
allyl sulﬁde compounds via activation of constitutive androstane receptor and
nuclear factor E2-related factor 2. Drug. Metab. Dispos. 35, 995–1000. doi:
10.1124/dmd.106.014340
Fox, K. A., Longo, M., Tamayo, E., Kechichian, T., Bytautiene, E., Hankins, G. D.,
et al. (2011). Effects of pravastatin on mediators of vascular function in a mouse
model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am. J. Obstet.
Gynecol. 205, 366e1–366e5. doi: 10.1016/j.ajog.2011.06.083
Geenes, V., and Williamson, C. (2009). Intrahepatic cholestasis of pregnancy. World
J. Gastroenterol. 15, 2049–2066. doi: 10.3748/wjg.15.2049
George, E. M., and Granger, J. P. (2011). Endothelin: key mediator of hyper-
tension in preeclampsia. Am. J. Hypertens. 24, 964–969. doi: 10.1038/ajh.
2011.99
Gerber, H. P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H., Meng, G.,
et al. (2002). VEGF regulates haematopoietic stem cell survival by an inter-
nal autocrine loop mechanism. Nature 417, 954–958. doi: 10.1038/nature
00821
Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology May 2014 | Volume 5 | Article 119 | 10
Cindrova-Davies New therapeutic targets for preeclampsia
Gilbert, J. S., Babcock, S. A., and Granger, J. P. (2007). Hypertension produced
by reduced uterine perfusion in pregnant rats is associated with increased sol-
uble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142–1147. doi:
10.1161/HYPERTENSIONAHA.107.096594
Gilbert, J. S., Ryan,M. J., LaMarca, B. B., Sedeek,M.,Murphy, S. R., and Granger, J. P.
(2008). Pathophysiology of hypertension during preeclampsia: linking placental
ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 294,
H541–H550. doi: 10.1152/ajpheart.01113.2007
Girardi, G. (2014). Can statins prevent pregnancy complications? J. Reprod.
Immunol. 101–102, 161–167. doi:10.1016/j.jri.2013.07.005
Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and Ten
Dijke, P. (2002). Balancing the activation state of the endothelium via two dis-
tinct TGF-beta type I receptors. EMBO J. 21, 1743–1753. doi: 10.1093/emboj/21.
7.1743
Greenberg, S. G., Baker, R. S.,Yang,D., and Clark, K. E. (1997). Effects of continuous
infusion of endothelin-1 in pregnant sheep. Hypertension 30, 1585–1590. doi:
10.1161/01.HYP.30.6.1585
Hansson, G. K. (2005). Inﬂammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352, 1685–1695. doi: 10.1056/NEJMra043430
Haugen, M., Meltzer, H. M., Brantsaeter, A. L., Mikkelsen, T., Osterdal, M. L.,
Alexander, J., et al. (2008). Mediterranean-type diet and risk of preterm birth
among women in the Norwegian, Mother and Child Cohort Study (MoBa):
a prospective cohort study. Acta Obstet. Gynecol. Scand. 87, 319–324. doi:
10.1080/00016340801899123
Hetz, C., Chevet, E., and Harding, H. P. (2013). Targeting the unfolded pro-
tein response in disease. Nat. Rev. Drug Discov. 12, 703–719. doi: 10.1038/
nrd3976
Holwerda, K. M., Burke, S. D., Faas,M. M., Zsengeller, Z., Stillman, I. E., Kang, P. M.,
et al. (2014). Hydrogen sulﬁde attenuates sFlt1-induced hypertension and renal
damage by upregulating vascular endothelial growth factor. J. Am. Soc. Nephrol.
25, 717–725. doi: 10.1681/ASN.2013030291
Hongfang, J., Bailin, C., Bin, Z., Chunyu, Z., Xinmin, L., Weijin, Z., et al. (2006).
Effects of hydrogen sulﬁde onhypoxic pulmonary vascular structural remodeling.
Life Sci. 78, 1299–1309. doi: 10.1016/j.lfs.2005.07.009
Hu, Y., Chen, X., Pan, T. T., Neo, K. L., Lee, S. W., Khin, E. S., et al. (2008).
Cardioprotection induced by hydrogen sulﬁde preconditioning involves acti-
vation of ERK and PI3K/Akt pathways. Pﬂugers Arch. 455, 607–616. doi:
10.1007/s00424-007-0321-4
Hubel, C. A. (1999). Oxidative stress in the pathogenesis of preeclampsia. Proc. Soc.
Exp. Biol. Med. 222, 222–235. doi: 10.1046/j.1525-1373.1999.d01-139.x
Hung, T. H., Skepper, J. N., Charnock-Jones, D. S., and Burton, G. J. (2002).
Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human
placenta and possible etiological factor in preeclampsia. Circ. Res. 90, 1274–1281.
doi: 10.1161/01.RES.0000024411.22110.AA
Huppertz, B. (2008). Placental origins of preeclampsia: challenging the cur-
rent hypothesis. Hypertension 51, 970–975. doi: 10.1161/HYPERTENSION-
AHA.107.107607
Huppertz, B.,Weiss,G., andMoser,G. (2014). Trophoblast invasion andoxygenation
of the placenta: measurements versus presumptions. J. Reprod. Immunol. 101–
102, 74–79. doi: 10.1016/j.jri.2013.04.003
Irani, R., Zhang, Y., Zhou, C. C., Blackwell, S. C., Hicks, M. J., Ramin, S. M.,
et al. (2010). Autoantibody-mediated angiotensin receptor activation contributes
to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension 55,
1246–1253. doi: 10.1161/HYPERTENSIONAHA.110.150540
Jain, A., Olovsson, M., Burton, G. J., and Yung, H. W. (2012). Endothelin-1 induces
endoplasmic reticulum stress by activating the PLC-IP(3) pathway: implications
for placental pathophysiology in preeclampsia. Am. J. Pathol. 180, 2309–2320.
doi: 10.1016/j.ajpath.2012.03.005
Jauniaux, E., Jurkovic, D., and Campbell, S. (1995). Current topic: in vivo investiga-
tion of the placental circulations by Doppler echography. Placenta 16, 323–331.
doi: 10.1016/0143-4004(95)90089-6
Jauniaux, E., Ramsay, B., and Campbell, S. (1994). Ultrasonographic investigation
of placental morphologic characteristics and size during the second trimester
of pregnancy. Am. J. Obstet. Gynecol. 170(Pt 1), 130–137. doi: 10.1016/S0002-
9378(94)70397-3
Johal, T., Lees, C. C., Everett, T. R., and Wilkinson, I. B. (2013). The nitric oxide
pathway and possible therapeutic options in pre-eclampsia. Br. J. Clin. Pharmacol.
doi: 10.1111/bcp.12301 [Epub ahead of print].
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., Liu, Z. G., and Neckers, L.
(2003). Hypoxia-inducible factor induction by tumour necrosis factor in
normoxic cells requires receptor-interacting protein-dependent nuclear fac-
tor kappaB activation. Biochem. J. 370, 1011–1017. doi: 10.1042/BJ200
21279
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., and Neckers, L. (2003). Micro-
tubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-
1alpha protein. J. Biol. Chem. 278, 7445–7452. doi: 10.1074/jbc.M2098
04200
Jung, Y.-J., Jennifer, S., Sunmin, I., Jane, L., Trepel, L., and Neckers, N. (2003). IL-1b
mediated up-regulation of HIF-1a via an NFkB/COX-2 pathway identiﬁes HIF-1
as a critical link between inﬂammation and oncogenesis. FASEB J. 17, 2115–2117.
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., et al. (1989).
Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science
246, 1309–1312. doi: 10.1126/science.2479987
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H.,
et al. (1996). Identiﬁcation of vascular endothelial growth factor determinants
for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF
variants by site-directed mutagenesis. J. Biol. Chem. 271, 5638–5646. doi:
10.1074/jbc.271.10.5638
Kingdom, J. C., and Kaufmann, P. (1997). Oxygen and placental villous develop-
ment: origins of fetal hypoxia. Placenta 18, 613–621; discussion 623–626. doi:
10.1016/S0143-4004(97)90000-X
Kondo, K., Bhushan, S., King, A. L., Prabhu, S. D., Hamid, T., Koenig, S., et al.
(2013). H(2)S protects against pressure overload-induced heart failure via upreg-
ulation of endothelial nitric oxide synthase. Circulation 127, 1116–1127. doi:
10.1161/CIRCULATIONAHA.112.000855
Kourembanas, S., McQuillan, L. P., Leung, G. K., and Faller, D. V. (1993). Nitric
oxide regulates the expression of vasoconstrictors and growth factors by vascular
endothelium under both normoxia and hypoxia. J. Clin. Invest. 92, 99–104. doi:
10.1172/JCI116604
Kumasawa, K., Ikawa, M., Kidoya, H., Hasuwa, H., Saito-Fujita, T., Morioka, Y.,
et al. (2011). Pravastatin induces placental growth factor (PGF) and ameliorates
preeclampsia in a mouse model. Proc. Natl. Acad. Sci. U.S.A. 108, 1451–1455. doi:
10.1073/pnas.1011293108
Laresgoiti-Servitje, E. (2010). A leading role for the immune system in the patho-
physiology of preeclampsia. J. Leukoc. Biol. 94, 247–257. doi: 10.1189/jlb.1112603
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., et al. (2007).
AutocrineVEGF signaling is required for vascular homeostasis. Cell 130, 691–703.
doi: 10.1016/j.cell.2007.06.054
Lees, C., Langford, E., Brown, A. S., de Belder, A., Pickles, A., Martin, J. F., et al.
(1996). The effects of S-nitrosoglutathione on platelet activation, hypertension,
and uterine and fetal Doppler in severe preeclampsia. Obstet. Gynecol. 88, 14–19.
doi: 10.1016/0029-7844(96)00070-1
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989).
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246,
1306–1309. doi: 10.1126/science.2479986
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., et al. (2006).
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
N. Engl. J. Med. 355, 992–1005. doi: 10.1056/NEJMoa055352
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H, England, L. J., Yu, K. F., et al.
(2004). Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J.
Med. 350, 672–683. doi: 10.1056/NEJMoa031884
Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., and Persico, M. G. (1991).
Isolation of a human placenta cDNA coding for a protein related to the vas-
cular permeability factor. Proc. Natl. Acad. Sci. U.S.A. 88, 9267–9271. doi:
10.1073/pnas.88.20.9267
Mayhew, T. M., Charnock-Jones, D. S., and Kaufmann, P. (2004). Aspects of human
fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated
pregnancies. Placenta 25, 127–139. doi: 10.1016/j.placenta.2003.10.010
Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., et al. (2003).
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to
endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin.
Invest. 111, 649–658. doi: 10.1172/JCI17189
Maynard, S. E., Venkatesha, S., Thadhani, R., and Karumanchi, S. A.
(2005). Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in
the pathogenesis of preeclampsia. Pediatr. Res. 57(Pt 2), 1R–7R. doi:
10.1203/01.PDR.0000159567.85157.B7
www.frontiersin.org May 2014 | Volume 5 | Article 119 | 11
Cindrova-Davies New therapeutic targets for preeclampsia
McDonald, S. D., Malinowski, A., Zhou, Q., Yusuf, S., and Devereaux, P.
J. (2008). Cardiovascular sequelae of preeclampsia/eclampsia: a systematic
review and meta-analyses. Am. Heart J. 156, 918–930. doi: 10.1016/j.ahj.2008.
06.042
Miles, E. W., and Kraus, J. P. (2004). Cystathionine beta-synthase: structure, func-
tion, regulation, and location of homocystinuria-causing mutations. J. Biol.
Chem. 279, 29871–29874. doi: 10.1074/jbc.R400005200
Mongraw-Chafﬁn, M. L., Cirillo, P. M., and Cohn, B. A. (2010). Preeclampsia
and cardiovascular disease death: prospective evidence from the child health and
development studies cohort. Hypertension 56, 166–171. doi: 10.1161/HYPER-
TENSIONAHA.110.150078
Muchova, L., Wong, R. J., Hsu, M., Morioka, I., Vitek, L., Zelenka, J., et al. (2007).
Statin treatment increases formation of carbon monoxide and bilirubin in mice:
a novel mechanism of in vivo antioxidant protection. Can. J. Physiol. Pharmacol.
85, 800–810. doi: 10.1139/Y07-077
Murphy, S. R., Babbette, B., LaMarca D., Cockrell, K., and Granger, J. P. (2010).
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced
hypertension in pregnant rats. Hypertension 55, 394–398. doi: 10.1161/HYPER-
TENSIONAHA.109.141473
Murphy, S. R., LaMarca, B., Cockrell, K., Arany, M., and Granger, J. P.
(2011). L-arginine supplementation abolishes the blood pressure and endothelin
response to chronic increases in plasma sFlt-1 in pregnant rats. Am. J. Phys-
iol. Regul. Integr. Comp. Physiol. 302, R259–R263. doi: 10.1152/ajpregu.003
19.2011
Mutter, W. P., and Karumanchi, S. A. (2008). Molecular mechanisms of preeclamp-
sia. Microvasc. Res. 75, 1–8. doi: 10.1016/j.mvr.2007.04.009
Nagamatsu, T., Fujii, T., Kusumi, M., Zou, L., Yamashita, T., Osuga, Y., et al.
(2004). Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expres-
sion under reduced oxygen: an implication for the placental vascular development
and the pathophysiology of preeclampsia. Endocrinology 145, 4838–4845. doi:
10.1210/en.2004-0533
Nova, A., Sibai, B. M., Barton, J. R., Mercer, B. M., and Mitchell, M. D. (1991).
Maternal plasma level of endothelin is increased in preeclampsia. Am. J. Obstet.
Gynecol. 165, 724–727. doi: 10.1016/0002-9378(91)90317-K
Oshima, M., Oshima, H., and Taketo, M. M. (1996). TGF-beta receptor type II
deﬁciency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev.
Biol. 179, 297–302. doi: 10.1006/dbio.1996.0259
Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O.,
et al. (2006). Chemical chaperones reduce ER stress and restore glucose home-
ostasis in a mouse model of type 2 diabetes. Science 313, 1137–1140. doi:
10.1126/science.1128294
Park, J. E., Chen, H. H., Winer, J., Houck, K. A., and Ferrara, N. (1994). Placenta
growth factor. Potentiation of vascular endothelial growth factor bioactivity, in
vitro and in vivo, and high afﬁnity binding to Flt-1 but not to Flk-1/KDR. J. Biol.
Chem. 269, 25646–25654.
Parrish, M., Murphy, S. R., Rutland, S., Wallace, K., Wenzel, K., Wallukat, G., et al.
(2010). The effect of immune factors, tumor necrosis factor-alpha, and agonistic
autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1
and soluble endoglin production in response to hypertension during pregnancy.
Am. J. Hypertens. 23, 911–916. doi: 10.1038/ajh.2010.70
Polhemus, D., Kondo, K., Bhushan, S., Bir, S. C., Kevil, C. G., Murohara, T.,
et al. (2013). Hydrogen sulﬁde attenuates cardiac dysfunction following heart
failure via induction of angiogenesis. Circ. Heart Fail. 6, 1077–1086. doi:
10.1161/CIRCHEARTFAILURE.113.000299
Poston, L., Briley, A. L., Seed, P. T., Kelly, F. J., and Shennan, A. H. (2006).
Vitamin, C. and vitamin E in pregnant women at risk for pre-eclampsia
(VIP trial): randomised placebo-controlled trial. Lancet 367, 1145–1154. doi:
10.1016/S0140-6736(06)68433-X
Poston, L., Igosheva, N., Mistry, H. D., Seed, P. T., Shennan, A. H., Rana,
S., et al. (2011). Role of oxidative stress and antioxidant supplementation
in pregnancy disorders. Am. J. Clin. Nutr. 94(Suppl.), 1980S–1985S. doi:
10.3945/ajcn.110.001156
Redecha, P., van Rooijen, N., Torry, D., and Girardi, G. (2009). Pravastatin prevents
miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 113,
4101–4109. doi: 10.1182/blood-2008-12-194258
Redman, C. W. G., and Sargent, I. L. (2000). Placental debris, oxida-
tive stress and pre-eclampsia. Placenta 21, 597–602. doi: 10.1053/plac.
2000.0560
Redman, C. W., and Sargent, I. L. (2005). Latest advances in understanding
preeclampsia. Science 308, 1592–1594. doi: 10.1126/science.1111726
Redman, C. W., Sargent, I. L., and Staff, A. C. (2014). IFPA Senior Award Lecture:
making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta
35(Suppl.), S20–S25. doi: 10.1016/j.placenta.2013.12.008
Roberts, J. M. (1998). Endothelial dysfunction in preeclampsia. Semin. Reprod.
Endocrinol. 16, 5–15. doi: 10.1055/s-2007-1016248
Roberts, J. M., and Cooper, D. W. (2001). Pathogenesis and genet-
ics of pre-eclampsia. Lancet 357, 53–56. doi: 10.1016/S0140-6736(00)
03577-7
Rolfo, A., Many, A., Racano, A., Tal, R., Tagliaferro, A., Letta, F., et al.
(2010). Abnormalities in oxygen sensing deﬁne early and late onset preeclamp-
sia as distinct pathologies. PLoS ONE 5:e13288. doi: 10.1371/journal.pone.00
13288
Rumbold, A. R., Crowther, C. A., Haslam, R. R., Dekker, G. A., and Robinson,
J. S. (2006). Vitamins, C. and E and the risks of preeclampsia and perina-
tal complications. N. Engl. J. Med. 354, 1796–1806. doi: 10.1056/NEJMoa
054186
Saad, A. F., Kechichian, T., Yin, H., Sbrana, E., Longo, M., Wen, M., et al. (2014).
Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse
model of preeclampsia. Reprod. Sci. 21, 138–145. doi: 10.1177/19337191134
92207
Sandrim, V. C., Palei, A. C., Metzger, I. F., Gomes, V. A., Cavalli, R. C.,
Tanus-Santos, J. E., et al. (2008). Nitric oxide formation is inversely related
to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-
1 and soluble endogline in preeclampsia. Hypertension 52, 402–407. doi:
10.1161/HYPERTENSIONAHA.108.115006
Savvidou, M. D., Hingorani, A. D., Tsikas, D., Frölich, J. C., Vallance, P., Nicolaides,
K. H., et al. (2003). Endothelial dysfunction and raised plasma concentra-
tions of asymmetric dimethylarginine in pregnant women who subsequently
develop pre-eclampsia. Lancet 361, 1511–1517. doi: 10.1016/S0140-6736(03)
13177-7
Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J.,
Espinola-Klein, C., et al. (2005). Asymmetric dimethylarginine and the risk
of cardiovascular events and death in patients with coronary artery dis-
ease: results from the AtheroGene Study. Circ. Res. 97, e53–e59. doi:
10.1161/01.RES.0000181286.44222.61
Sedeek, M., Gilbert, J. S., LaMarca, B. B., Sholook, M., Chandler, D. L., et al.
(2008). Role of reactive oxygen species in hypertension produced by reduced
uterine perfusion in pregnant rats. Am. J. Hypertens. 21, 1152–1156. doi:
10.1038/ajh.2008.239
Sen, N., Paul, B. D., Gadalla, M. M., Mustafa, A. K., Sen, T., Xu, R., et al. (2012).
Hydrogen sulﬁde-linked sulfhydration of NF-kappaB mediates its antiapoptotic
actions. Mol. Cell 45, 13–24. doi: 10.1016/j.molcel.2011.10.021
Shao, E. S., Lin, L., Yao, Y., and Boström, K. I. (2009). Expression of vas-
cular endothelial growth factor is coordinately regulated by the activin-like
kinase receptors 1 and 5 in endothelial cells. Blood 114, 2197–2206. doi:
10.1182/blood-2009-01-199166
Sibai, B., Dekker, G., and Kupferminc, M. (2005). Pre-eclampsia. Lancet 365, 785–
799. doi: 10.1016/S0140-6736(05)17987-2
Sodha, N. R., Clements, R. T., Feng, J., Liu, Y., Bianchi, C., Horvath, E. M., et al.
(2009). Hydrogen sulﬁde therapy attenuates the inﬂammatory response in a
porcine model of myocardial ischemia/reperfusion injury. J. Thorac. Cardiovasc.
Surg. 138, 977–984. doi: 10.1016/j.jtcvs.2008.08.074
Steinberg, G., Khankin, E. V., and Karumanchi, S. A. (2009). Angiogenic factors
and preeclampsia. Thromb. Res. 123(Suppl. 2), S93–S99. doi: 10.1016/S0049-
3848(09)70020-9
Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar,
A., et al. (2003). Neutralization of circulating vascular endothelial growth fac-
tor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1)
induces proteinuria. J. Biol. Chem. 278, 12605–12608. doi: 10.1074/jbc.C3000
12200
Taylor, R. N., Grimwood, J., Taylor, R. S., McMaster, M. T., Fisher, S. J., North, R.
A., et al. (2003). Longitudinal serum concentrations of placental growth factor:
evidence for abnormal placental angiogenesis in pathologic pregnancies. Am. J.
Obstet. Gynecol. 188, 177–182. doi: 10.1067/mob.2003.111
Taylor, R. N., Varma, M., Teng, N. N., and Roberts, J. M. (1990). Women with
preeclampsia have higher plasma endothelin levels than women with normal
Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology May 2014 | Volume 5 | Article 119 | 12
Cindrova-Davies New therapeutic targets for preeclampsia
pregnancies. J. Clin. Endocrinol. Metab. 71, 1675–1677. doi: 10.1210/jcem-71-6-
1675
Vadillo-Ortega, F., Perichart-Perera, O., Espino, S., Avila-Vergara, M. A., Ibarra,
I., Ahued, R., et al. (2011). Effect of supplementation during pregnancy
with L-arginine and antioxidant vitamins in medical food on pre-eclampsia
in high risk population: randomised controlled trial. BMJ 342, d2901. doi:
10.1136/bmj.d2901
van Pampus, M. G., and Aarnoudse, J. G. (2005). Long-term out-
comes after preeclampsia. Clin. Obstet. Gynecol. 48, 489–494. doi:
10.1097/01.grf.0000160316.67359.3d
Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y. M., et al.
(2006). Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat.
Med. 12, 642–649. doi: 10.1038/nm1429
Walsh, S. W. (1998). Maternal-placental interactions of oxidative stress and
antioxidants in preeclampsia. Semin. Reprod. Endocrinol. 16, 93–104. doi:
10.1055/s-2007-1016256
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C. H.
(1994). Different signal transduction properties of KDR and Flt1, two receptors
for vascular endothelial growth factor. J. Biol. Chem. 269, 26988–26995.
Wang, K., Ahmad, S., Cai, M., Rennie, J., Fujisawa, T., Crispi, F., et al. (2013).
Dysregulation of hydrogen sulﬁde producing enzyme cystathionine gamma-lyase
contributes to maternal hypertension and placental abnormalities in preeclamp-
sia. Circulation 127, 2514–2522. doi: 10.1161/CIRCULATIONAHA.113.
001631
Wang, M. J., Cai, W. J., Li, N., Ding, Y. J., Chen, Y., Zhu, Y. C., et al. (2010).
The hydrogen sulﬁde donor NaHS promotes angiogenesis in a rat model of
hind limb ischemia. Antioxid. Redox Signal. 12, 1065–1077. doi: 10.1089/ars.
2009.2945
Wang, R. (2009). Is H2S a stinky remedy for atherosclerosis? Arterioscler. Thromb.
Vasc. Biol. 29, 156–157. doi: 10.1161/ATVBAHA.108.180190
Xu, C., Bailly-Maitre, B., and Reed, J. C. (2005). Endoplasmic reticulum stress: cell
life and death decisions. J. Clin. Invest. 115, 2656–2664. doi: 10.1172/JCI26373
Yang, G.,Wu, L., Jiang, B., Yang,W., Qi, J., Cao, K., et al. (2008). H2S as a physiologic
vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase.
Science 322, 587–590. doi: 10.1126/science.1162667
Yong, Q. C., Tang, Z. H., Xie, W., Shen, X. T., Liu, M. H., Peng, X. P., et al.
(2008). Endogenous hydrogen sulphide mediates the cardioprotection induced
by ischemic postconditioning. Am. J. Physiol. Heart Circ. Physiol. 295, H1330–
H1340. doi: 10.1152/ajpheart.00244.2008
Yoshida,H. (2007). ER stress anddiseases. FEBS J.274, 630–658. doi: 10.1111/j.1742-
4658.2007.05639.x
Young, B. C., Levine, R. J., andKarumanchi, S.A. (2010). Pathogenesis of preeclamp-
sia. Annu. Rev. Pathol. 5, 173–192. doi: 10.1146/annurev-pathol-121808-102149
Yung, H. W., Calabrese, S., Hynx, D., Hemmings, B. A., Cetin, I., Charnock-Jones,
D. S., et al. (2008). Evidence of placental translation inhibition and endoplasmic
reticulum stress in the etiology of human intrauterine growth restriction. Am. J.
Pathol. 173, 451–462. doi: 10.2353/ajpath.2008.071193
Yung, H. W., Hemberger, M., Watson, E. D., Senner, C. E., Jones, C. P., Kaufman, R.
J., et al. (2012). Endoplasmic reticulum stress disrupts placental morphogenesis:
implications for human intrauterine growth restriction. J. Pathol. 228, 554–564.
doi: 10.1002/path.4068
Zhang, K., and Kaufman, R. J. (2008). From endoplasmic-reticulum stress
to the inﬂammatory response. Nature 454, 455–462. doi: 10.1038/nature
07203
Zhao, W., Zhang, J., Lu, Y., and Wang, R. (2001). The vasorelaxant effect of H(2)S
as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 20, 6008–6016.
doi: 10.1093/emboj/20.21.6008
Zhou, C., Ahmad, S., Mi, T., Abbasi, S., Xia, L., Day, M. C. (2008). Autoantibody
from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 pro-
duction via angiotensin type 1 receptor and calcineurin/nuclear factor of activated
T-cells signaling. Hypertension 51, 1010–1019. doi: 10.1161/HYPERTENSION-
AHA.107.097790
Zhou, J., and Brüne, B. (2006). Cytokines and hormones in the regulation of hypoxia
inducible factor-1alpha (HIF-1alpha). Cardiovasc. Hematol. Agents Med. Chem.
4, 189–197. doi: 10.2174/187152506777698344
Zhu, H., Itoh, K., Yamamoto, M., Zweier, J. L., and Li, Y. (2005). Role of Nrf2
signaling in regulation of antioxidants and phase 2 enzymes in cardiac ﬁbroblasts:
protection against reactive oxygen and nitrogen species-induced cell injury. FEBS
Lett. 579, 3029–3036. doi: 10.1016/j.febslet.2005.04.058
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 31 March 2014; accepted: 02 May 2014; published online: 27 May 2014.
Citation: Cindrova-Davies T (2014) The therapeutic potential of antioxidants, ER
chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front.
Pharmacol. 5:119. doi: 10.3389/fphar.2014.00119
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a
section of the journal Frontiers in Pharmacology.
Copyright © 2014 Cindrova-Davies. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org May 2014 | Volume 5 | Article 119 | 13
